NCT02035020View on ClinicalTrials.gov

A Phase IIa Trial to Test Safety and Efficacy Interferon Gamma Treatment in Elevating Frataxin Levels in FRDA Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

July 30, 2014

Study Completion Date

July 30, 2014

Conditions
Friedreich Ataxia
Interventions
DRUG

gamma interferon

IFN gamma 1b (Immukin ®) will be administered by subcutaneous route at day 0, 14 and 28 at a dose of 100, 150 and 200 ug respectively.

Trial Locations (1)

00161

Policlinico Umberto I°, Rome

All Listed Sponsors
lead

Azienda Policlinico Umberto I

OTHER

NCT02035020 - A Phase IIa Trial to Test Safety and Efficacy Interferon Gamma Treatment in Elevating Frataxin Levels in FRDA Patients | Biotech Hunter | Biotech Hunter